Literature DB >> 9330631

High-efficiency retroviral infection of primary myoblasts.

M L Springer1, H M Blau.   

Abstract

In the past, it has been hard to introduce genes into primary myoblasts without selection, as they have been very difficult to transfect or infect. We describe conditions under which mouse primary skeletal muscle myoblasts can be infected with retroviral vectors at high efficiency. Infection can be greatly increased by minimizing the time during which cells are exposed to virus, adding a minimal centrifugation step, and supplementing the infection cocktail to mimic more closely primary myoblast growth medium. Under these conditions, one round of exposure to virus results in an infection efficiency of up to 80%, whereas 4-5 rounds of infection over a two day period reproducibly yield an infection efficiency of > 99%. These methods greatly enhance the potential for studying genetically engineered primary myoblasts from any mouse strain, transgenic or knockout, and may have useful application to other primary cell types that are refractory to transfection or infection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9330631     DOI: 10.1007/bf02721371

Source DB:  PubMed          Journal:  Somat Cell Mol Genet        ISSN: 0740-7750


  33 in total

1.  Generation of human adult mesenchymal stromal/stem cells expressing defined xenogenic vascular endothelial growth factor levels by optimized transduction and flow cytometry purification.

Authors:  Uta Helmrich; Anna Marsano; Ludovic Melly; Thomas Wolff; Liliane Christ; Michael Heberer; Arnaud Scherberich; Ivan Martin; Andrea Banfi
Journal:  Tissue Eng Part C Methods       Date:  2011-12-19       Impact factor: 3.056

Review 2.  Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis.

Authors:  Georges von Degenfeld; Andrea Banfi; Matthew L Springer; Helen M Blau
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

3.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis.

Authors:  Clare R Ozawa; Andrea Banfi; Nicole L Glazer; Gavin Thurston; Matthew L Springer; Peggy E Kraft; Donald M McDonald; Helen M Blau
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

4.  Balanced single-vector co-delivery of VEGF/PDGF-BB improves functional collateralization in chronic cerebral ischemia.

Authors:  Aiki Marushima; Melina Nieminen; Irina Kremenetskaia; Roberto Gianni-Barrera; Johannes Woitzik; Georges von Degenfeld; Andrea Banfi; Peter Vajkoczy; Nils Hecht
Journal:  J Cereb Blood Flow Metab       Date:  2019-01-09       Impact factor: 6.200

5.  A gene-trap strategy identifies quiescence-induced genes in synchronized myoblasts.

Authors:  Ramkumar Sambasivan; Grace K Pavlath; Jyotsna Dhawan
Journal:  J Biosci       Date:  2008-03       Impact factor: 1.826

6.  Highly conserved RNA sequences that are sensors of environmental stress.

Authors:  A Spicher; O M Guicherit; L Duret; A Aslanian; E M Sanjines; N C Denko; A J Giaccia; H M Blau
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

7.  Graded transcriptional response to different concentrations of a single transactivator.

Authors:  A M Kringstein; F M Rossi; A Hofmann; H M Blau
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

8.  The molecular chaperone HSP70 binds to and stabilizes NOD2, an important protein involved in Crohn disease.

Authors:  Vishnu Mohanan; Catherine Leimkuhler Grimes
Journal:  J Biol Chem       Date:  2014-04-30       Impact factor: 5.157

9.  microRNA-1 and microRNA-206 regulate skeletal muscle satellite cell proliferation and differentiation by repressing Pax7.

Authors:  Jian-Fu Chen; Yazhong Tao; Juan Li; Zhongliang Deng; Zhen Yan; Xiao Xiao; Da-Zhi Wang
Journal:  J Cell Biol       Date:  2010-09-06       Impact factor: 10.539

10.  RIP2, a checkpoint in myogenic differentiation.

Authors:  Barbara Munz; Eberhard Hildt; Matthew L Springer; Helen M Blau
Journal:  Mol Cell Biol       Date:  2002-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.